Search results for "Concomitant"

showing 10 items of 248 documents

Headache attributed to aeroplane travel: the first multicentric survey in a paediatric population affected by primary headaches

2018

BACKGROUND: This multicentric survey investigates the prevalence and characteristics of Airplane Headache in children affected by primary headaches. METHODS: Patients with symptoms of Airplane Headache were recruited from nine Italian Pediatric Headache Centres. Each patient was handed a structured questionnaire which met the ICHD-III criteria. RESULTS: Among 320 children suffering from primary headaches who had flights during their lifetime, 15 (4.7%) had Airplane Headache, with mean age of 12.4 years. Most of the patients were females (80%). The headache was predominantly bilateral (80%) and localized to the frontal area (60%); it was mainly pulsating, and lasted less than 30 min in all c…

MalePediatricsNeurologyPhotophobiaAircraftHeadache Disorderlcsh:MedicineAirplane0302 clinical medicinePhotophobiaSurveys and QuestionnairesSurveys and Questionnaire030212 general & internal medicineChildChildrenAeroplane travelPain MeasurementTravelICHD-IIIHeadacheGeneral MedicinePediatric headachePhonophobiaItalyChild PreschoolFemalemedicine.symptomResearch ArticleHumanAdultmedicine.medical_specialtyAdolescentHeadache Disorders03 medical and health sciencesPrimary headachePrimary headachePrimary headachesmedicineHumansPreschoolAeroplane travel; Airplane; Children; Headache; ICHD-III; Pediatric headache; Primary headaches; Adolescent; Adult; Child; Child Preschool; Female; Headache Disorders; Humans; Italy; Male; Pain Measurement; Photophobia; Aircraft; Surveys and Questionnaires; Travelbusiness.industrylcsh:RMean agePediatric headacheAnesthesiology and Pain MedicineConcomitantNeurology (clinical)business030217 neurology & neurosurgeryPaediatric population
researchProduct

An epidemiological study of dental agenesis in a primary health area in Spain : estimated prevalence and associated factors

2010

Objectives: To evaluate the prevalence of dental agenesis and its possible association with other developmental dental anomalies and systemic entities. Setting and Sample Population: Descriptive transversal study, for which 1518 clinical records, of patients visited by the Odontological Service of the Primary Health Centre of Cassà de la Selva (Girona-Spain) between December 2002 and February 2006 were reviewed. The data were recorded in relation to the oral and dental anomalies and the associated systemic entities, between the ones referred as concomitant in literature. Results: Values of 9.48% (7.25% excluding the third molars) for dental agenesis and 0.39% for oligodontia were obtained. …

MalePediatricsmedicine.medical_specialtyCataloniaDentistryCentres d'atenció primàriaOligodontia03 medical and health sciences0302 clinical medicinePatologia dentalCatchment Area Healthstomatognathic systemGenetic etiologyRisk FactorsPrimary healthEpidemiologymedicinePrevalenceDentitionHumansEspanyaGeneral Dentistry030304 developmental biologyAnodontia0303 health sciencesDental anomaliesPrimary Health Carebusiness.industryDental agenesisCatalunyaCommunity health services030206 dentistryDentició:CIENCIAS MÉDICAS [UNESCO]3. Good healthstomatognathic diseasesOtorhinolaryngologySpainConcomitantUNESCO::CIENCIAS MÉDICASSurgeryFemalebusinessClinical recordDental pathology
researchProduct

The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-…

2003

To evaluate immune responses, safety and reactogenicity of the concomitant use of DTaP-IPV-Hib and the newly available 7-valent pneumococcal conjugate (7VPnC) vaccines when given as the primary immunization series in early infancy. A total of 231 healthy infants were enrolled at 11 German study centers and randomized to receive either 7VPnC plus DTaP-IPV-Hib vaccines concomitantly into opposite limbs at age 2, 3, 4 and 11-15 months (7VPnC group) or DTaP-IPV-Hib vaccine at the same ages plus a 7VPnC "catch-up vaccination" at ages 6, 7, 8 and 11-15 months (Control group). Blood samples were drawn before and 4 weeks after the first three vaccine doses and 4 weeks after the fourth dose. Local a…

MalePediatricsmedicine.medical_specialtyImmunization SecondaryEnzyme-Linked Immunosorbent AssayHerpesvirus VaccinesAntibodies ViralPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHerpesvirus 1 BovineReactogenicityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryDiphtheriaImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesImmunizationConcomitantChild PreschoolImmunologyMolecular MedicineFemalePertactinbusinessmedicine.drugVaccine
researchProduct

European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of …

2020

ObjectiveThe best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.DesignInternational multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed.Results30 394 patients from 27 European countries were eval…

MaleRegistrieProton Pump InhibitorPractice Patterns0302 clinical medicineClarithromycinProspective StudiesRegistriesPractice Patterns Physicians'[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologyGastroenterologyMiddle AgedAnti-Bacterial Agents3. Good healthEurope030220 oncology & carcinogenesisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemalemedicine.drugHumanAdultmedicine.medical_specialtyTRIPLE THERAPY ; QUADRUPLE THERAPY ; CONSENSUS ; INFECTION ; METAANALYSIS ; CLARITHROMYCIN ; GUIDELINES ; RESISTANCE ; ARTICLESettore MED/12 - GASTROENTEROLOGIAFirst lineHelicobacter Infections03 medical and health sciencesDrug TherapyInternal medicineAnti-Bacterial AgentmedicineHumansMedical prescriptionAdverse effectAgedPhysicians'Helicobacter pyloribusiness.industryhelicobacter pylori - treatmentProton Pump InhibitorsAmoxicillinHelicobacter pyloribiology.organism_classificationMetronidazoleProspective StudieConcomitanthelicobacter pyloribusinessHelicobacter Infection[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

25-Hydroxyvitamin D, IL-31, and IL-33 in Children with Allergic Disease of the Airways

2014

Low vitamin D is involved in allergic asthma and rhinitis. IL-31 and IL-33 correlate with Th2-associated cytokines in allergic disease. We investigated whether low vitamin D is linked with circulating IL-31 and IL-33 in children with allergic disease of the airways. 25-Hydroxyvitamin D [25(OH) Vit D], IL-31, and IL-33 plasma levels were measured in 28 controls (HC), 11 allergic rhinitis (AR) patients, and 35 allergic asthma with rhinitis (AAR) patients. We found significant lower levels of 25(OH) Vit D in AR and in AAR than in HC. IL-31 and IL-33 plasma levels significantly increased in AAR than HC. IL-31 and IL-33 positively correlated in AR and AAR. 25(OH) Vit D deficient AAR had higher l…

MaleRhinitis Allergic PerennialAdolescentArticle SubjectImmunologyDiseasemedicine.disease_causeAtopyAllergenlcsh:PathologymedicineVitamin D and neurologyHumansVitamin DRisk factorChildAsthmabusiness.industryInterleukinsCell BiologyInterleukin-33medicine.diseaseRhinitis AllergicInterleukin 33plasma IL-31 IL-33 Th2-associated cytokines.ConcomitantImmunologyAdolescent; Child; Female; Humans; Interleukin-33; Interleukins; Male; Rhinitis Allergic; Rhinitis Allergic Perennial; Vitamin DFemalebusinessResearch Articlelcsh:RB1-214Mediators of Inflammation
researchProduct

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

2013

Background: The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses when administered as 3 infant doses plus a toddler dose (3+1 schedule) or as an abbreviated schedule of 2 infant doses plus a toddler dose (2+1 schedule). The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine immunization programs. Objective: To summarize immunologic responses elicited by PCV13 administered in a 2+1 schedule and following 2 doses in a 3+1 schedule. Methods: Studies were double-blind, randomized, active-controlled, multicenter studies…

MaleSerotypePCV132+12+1; Immune response; PCV13; Pediatric; Pneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal conjugate vaccinePneumococcal VaccinesDouble-Blind MethodHumansMedicineDosingToddlerImmune responseMexicoPediatricGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfantAntibodies BacterialUnited KingdomClinical trialInfectious DiseasesItalySpainImmunoglobulin GConcomitantImmunologybiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drug
researchProduct

Factors reducing omalizumab response in severe asthma

2018

Background: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. Methods: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. Results: Age was an independent risk factor for a reduced response concerning FEV1%, FVC%, ACT and for a lower asthma control. O…

MaleSevere asthmaDrug ResistanceComorbidityOmalizumabOmalizumabAdrenal Cortex HormoneComorbidities0302 clinical medicineRetrospective StudieAdrenal Cortex HormonesRisk FactorsForced Expiratory VolumeAge FactorNasal polypsAnti-Asthmatic Agents030212 general & internal medicineMultivariate AnalysiSmokingAge FactorsReal-lifeMiddle AgedTreatment OutcomeItalyFemaleComorbiditieHumanmedicine.drugAdultage; comorbidities; obesity; omalizumab; real-life; severe asthma; therapeutic response; internal medicinemedicine.medical_specialtyLogistic ModelTherapeutic responseSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric Oxide03 medical and health sciencesFEV1/FVC ratioNasal PolypsAgeInternal medicineInternal MedicinemedicineAnti-Asthmatic AgentHumansObesityRisk factorRetrospective StudiesAsthmabusiness.industryRisk Factormedicine.diseaseComorbidityAsthmarespiratory tract diseasesLogistic Models030228 respiratory systemConcomitantMultivariate AnalysisExhaled nitric oxideNasal PolypAge; Comorbidities; Obesity; Omalizumab; Real-life; Severe asthma; Therapeutic responsebusinessEuropean Journal of Internal Medicine
researchProduct

Post-vaccine measles in a child with concomitant influenza, Sicily, Italy, March 2015

2015

We describe the occurrence of measles in an 18 month-old patient in Sicily, Italy, in March 2015, who received the first dose of a measles-containing vaccine seven days before onset of prodromal symptoms. Measles virus infection was confirmed by PCR and detection of specific immunoglobulin; viral genotyping permitted the confirmation of a vaccine-associated illness. The patient had a concurrent influenza virus infection, during a seasonal epidemic outbreak of influenza.

MaleTime FactorsMeasles-Mumps-Rubella VaccineGenotypeEpidemiologyAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataMeaslesPolymerase Chain ReactionVirusMeasles virusChickenpox VaccineVirologymedicineHumansVaccines CombinedGenotypingChickenpox Vaccinebiologybusiness.industryPublic Health Environmental and Occupational HealthInfantmedicine.diseasebiology.organism_classificationVirologyMEASLES INFLUENZA VACCINESImmunoglobulin MItalyImmunoglobulin MMeasles virusConcomitantbiology.proteinFemalebusinessMeasles-Mumps-Rubella VaccineMeasles
researchProduct

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-h…

2015

AbstractObjectiveLomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis affected the lipid-lowering efficacy of lomitapide.MethodsExisting lipid-lowering therapy, including apheresis, was to remain stable from Week −6 to Week 26. Lomitapide dose was escalated on the basi…

MaleTime FactorsSettore MED/09 - Medicina InternaGastroenterologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundLipoprotein apheresisMedicineHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol LDL; Combined Modality Therapy; Female; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Phenotype; Time Factors; Treatment Outcome; Young Adult; Homozygote; Cardiology and Cardiovascular MedicinebiologyAnticholesteremic AgentsHomozygoteLipoprotein(a)Combined Modality TherapyCholesterolPhenotypeTreatment OutcomeBlood Component Removallipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySocio-culturaleLipoprotein apheresiArticleLDLHyperlipoproteinemia Type IIYoung AdultHomozygous familial hypercholesterolaemiaInternal medicinePost-hoc analysisHumansGenetic Predisposition to DiseaseHomozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; Cardiology and Cardiovascular Medicinebusiness.industryCholesterol LDLLomitapideLomitapideEndocrinologyApheresischemistryConcomitantAdjunctive treatmentbiology.proteinBenzimidazolesbusinessBiomarkersLipoprotein(a)Atherosclerosis
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct